Primary HIV infection: An update;Primo-infection VIH: Mise au point

Revue Medicale Suisse

Volumn 1, Issue 36, 2005, Pages 2310-2314

  Schiffer, Véronique ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHADENOPATHY; MONONUCLEOSIS; MYALGIA; PRIMARY INFECTION; RASH; REVIEW; SEROCONVERSION; SYMPTOMATOLOGY; TREATMENT INDICATION; VIRUS LOAD; VIRUS TRANSMISSION; ARTICLE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; MEDICAL ETHICS; RISK FACTOR; TIME;

ANTI-HIV AGENTS; DIAGNOSIS, DIFFERENTIAL; ETHICS, MEDICAL; HIV INFECTIONS; HUMANS; RISK FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 32944456388     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Weintrob AC, Giner J, Menezes P, et al. Infrequent diagnosis of primary human immunodeficiency virus infection: Missed opportunities in acute care settings. Arch Intern Med 2003;163:2097-100.
2. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. Aids 2001;15:2287-92.
3. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988;148:945-9.
4. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: Consequences for subsequent course of infection. Bmj 1989;299:154-7.
5. Vanhems P, Voirin N, Hirschel B, et al. Brief report: Incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS. J Acquir Immune Defic Syndr 2003;32:542-4.
6. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354:729-33.
7. Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: Is the diagnosis too restrictive? Clin Infett Dis 1997;24:965-70.
8. Kinloch-de Loes S, de Saussure P, Saurat JH, Stalder H, Hirschel B, Perrin LH. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases. Clin Infect Dis 1993;17:59-65.
9. Zaunders J, Carr A, McNally L, Penny R, Cooper DA. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. Aids 1995;9:561-6.
10. Schiffer V, Deveau C, Meyer L, et al. Recent changes in the management of primary HIV-1 infection: Results from the French PRIMO cohort. HIV Med 2004;5:326-33.
11. Schacker T, Little S, Connick E, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: Implications for timing of antiretroviral therapy. J Infect Dis 2000;181:354-7.
12. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to aids. J Infect Dis 2001;183:1466-75.
13. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
14. Smith D, Berrey MM, Robertson M, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:950-4.
15. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2000;97:3382-7.
16. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
17. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. Aids 2003;17:2479-86.
18. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited Durability of Viral Control following Treated Acute HIV Infection. Plos Med 2004;1:e36. Epub 2004 Oct 26.
19. Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? Aids 2004;18:2361-9.
20. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: An uncommon phenomenon? Clin Infect Dis 2005;40:1350-4. Epub 2005 Mar 31.
21. Fidler S, Oxenius A, Brady M, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. Aids 2002;16:2049-54.
22. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Flammarion, 2004.
23. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM: Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? Aids 2004;18:709-18.